289 related articles for article (PubMed ID: 21536392)
1. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
2. Relationship between isotope half-life and prostatic edema for optimal prostate dose coverage in permanent seed implants.
Villeneuve M; Leclerc G; Lessard E; Pouliot J; Beaulieu L
Med Phys; 2008 May; 35(5):1970-7. PubMed ID: 18561673
[TBL] [Abstract][Full Text] [Related]
3. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
4. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
5. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
6. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
8. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
[TBL] [Abstract][Full Text] [Related]
9. Prescription dose in permanent (131)Cs seed prostate implants.
Yue N; Heron DE; Komanduri K; Huq MS
Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dosimetric and biologic effective dose parameters for prostate and urethra using 131 Cs and 125 I for prostate permanent implant brachytherapy.
Sahgal A; Jabbari S; Chen J; Pickett B; Roach M; Weinberg V; Hsu IC; Pouliot J
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):247-54. PubMed ID: 18722275
[TBL] [Abstract][Full Text] [Related]
11. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
12. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
13. Comparison of seed loading approaches in prostate brachytherapy.
Butler WM; Merrick GS; Lief JH; Dorsey AT
Med Phys; 2000 Feb; 27(2):381-92. PubMed ID: 10718143
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of low energy brachytherapy Monte Carlo dose calculations to uncertainties in human tissue composition.
Landry G; Reniers B; Murrer L; Lutgens L; Gurp EB; Pignol JP; Keller B; Beaulieu L; Verhaegen F
Med Phys; 2010 Oct; 37(10):5188-98. PubMed ID: 21089752
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
16. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].
Herein A; Ágoston P; Szabó Z; Jorgo K; Markgruber B; Pesznyák C; Polgár C; Major T
Magy Onkol; 2015 Jun; 59(2):148-53. PubMed ID: 26035163
[TBL] [Abstract][Full Text] [Related]
17. Influence of prostatic edema on 131Cs permanent prostate seed implants: a dosimetric and radiobiological study.
Kehwar TS; Jones HA; Huq MS; Smith RP
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):621-7. PubMed ID: 20932692
[TBL] [Abstract][Full Text] [Related]
18. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
19. Brachytherapy in patients with small prostate glands.
Loblaw DA; Wallner K; Dibiase S; Russell K; Blasko J; Ellis W
Tech Urol; 2000 Jun; 6(2):64-9. PubMed ID: 10798802
[TBL] [Abstract][Full Text] [Related]
20. Effect of planning margin on dosimetric quality in 131Cs permanent prostate brachytherapy.
Li T; Fountain BL; Duffy EW
Brachytherapy; 2010; 9(2):159-64. PubMed ID: 19853535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]